15-aa C-terminal lipolytic fragment of human GH (residues 177-191) plus an N-terminal tyrosine. Proposed to retain GH's lipolytic / antilipogenic activity without the diabetogenic full-molecule effects. FDA phase 2 obesity trials failed to show weight loss. Marketing claims far outpace evidence.
Dosing Guidelines
Subcutaneous (SC): Typical 333 mcg (Range: 250–500 mcg)